Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp. develops and markets interventional MRI medical devices for incision-free tissue ablation. Its recurring news centers on TULSA-PRO® and the TULSA Procedure™, which use real-time MRI guidance, robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue in prostate cancer and benign prostatic hyperplasia.
Company updates also cover Sonalleve®, an MRI-guided therapy used for pain palliation of bone metastases, desmoid tumors and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. Recurring developments include financial results, revenue guidance, payer coverage, CAPTAIN post-market clinical data, scientific-meeting presentations, treatment-site adoption milestones and investor conference updates.
Profound Medical Corp. (NASDAQ: PROF) plans to announce its fourth quarter and full year 2020 financial results on March 2, 2021, post-market close. Management will host a conference call at 4:30 p.m. ET for reviewing these results and discussing business developments. Profound specializes in customizable, incision-free therapies, notably TULSA-PRO® for prostate ablation and Sonalleve® for treating uterine fibroids. The company's technologies are CE marked, FDA cleared, and hold various international approvals.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) plans to release its third quarter 2020 financial results on November 5, 2020, after market close. A conference call to discuss the findings will occur at 4:30 p.m. ET the same day. Profound is a leading medical device company specializing in customizable, incision-free therapies for tissue ablation. Its key technologies include TULSA-PRO®, designed for radiation-free prostate ablation, and Sonalleve®, which treats uterine fibroids and palliative pain. Both technologies have received necessary regulatory approvals, enhancing the company's market position.
Profound Medical Corp. (NASDAQ:PROF) announced an upcoming presentation at the Cantor Virtual Global Healthcare Conference on September 17, 2020, at 11:20 a.m. ET. The company focuses on customizable, incision-free therapies for the ablation of diseased tissue using real-time MRI and ultrasound technology. Their key products include TULSA-PRO, designed for prostate cancer treatment, and Sonalleve, targeting uterine fibroids and pain management. Both technologies have received multiple regulatory approvals, enhancing their market potential.